Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNA Ginkgo Bioworks	$12.91 -2.7%	$11.10	$5.00 ▼ $16.85	$776.13M	1.5	1.83 million shs	1.53 million shs
QURE uniQure	$15.78 +8.1%	$14.64	$4.45 ▼ $19.18	$801.06M	0.11	1.30 million shs	1.55 million shs
STOK Stoke Therapeutics	$17.17 +1.5%	$12.41	$5.35 ▼ $17.61	$926.62M	1.15	853,602 shs	1.64 million shs
TIL Instil Bio	$28.25 +4.7%	$27.76	$9.90 ▼ $92.00	$176.89M	2.16	170,842 shs	94,451 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNA Ginkgo Bioworks	-3.46%	-2.69%	+36.94%	+62.94%	-15.08%
QURE uniQure	+8.08%	+17.32%	+13.04%	+15.18%	+135.52%
STOK Stoke Therapeutics	+1.54%	+29.58%	+46.13%	+75.92%	+22.91%
TIL Instil Bio	+4.75%	+8.91%	+18.35%	+93.10%	+170.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DNA Ginkgo Bioworks	0.9997 of 5 stars	1.2	3.0	0.0	1.8	2.5	0.6
QURE uniQure	2.8141 of 5 stars	3.5	1.0	0.0	3.9	2.5	0.6
STOK Stoke Therapeutics	4.1339 of 5 stars	3.6	1.0	4.8	2.5	0.8	1.3
TIL Instil Bio	3.1147 of 5 stars	3.5	4.0	0.0	1.1	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNA Ginkgo Bioworks	2.33	Hold	$8.50	-34.15% Downside
QURE uniQure	3.00	Buy	$37.45	137.35% Upside
STOK Stoke Therapeutics	3.25	Buy	$25.17	46.57% Upside
TIL Instil Bio	3.00	Buy	$119.00	321.24% Upside

Current Analyst Ratings Breakdown

Latest TIL, QURE, DNA, and STOK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	QURE uniQure	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$30.00
8/13/2025	STOK Stoke Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00
8/13/2025	STOK Stoke Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $22.00
8/8/2025	DNA Ginkgo Bioworks	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/30/2025	QURE uniQure	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$47.00
7/29/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $35.00
7/18/2025	STOK Stoke Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
7/1/2025	STOK Stoke Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
6/5/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$125.00 ➝ $125.00
6/2/2025	TIL Instil Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/30/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNA Ginkgo Bioworks	$227.04M	3.33	N/A	N/A	$10.47 per share	1.23
QURE uniQure	$27.12M	31.93	N/A	N/A	($0.07) per share	-225.43
STOK Stoke Therapeutics	$36.56M	25.74	N/A	N/A	$6.11 per share	2.81
TIL Instil Bio	N/A	N/A	N/A	N/A	$25.96 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNA Ginkgo Bioworks	-$547.03M	-$5.86	N/A	N/A	N/A	-136.56%	-43.25%	-22.29%	N/A
QURE uniQure	-$239.56M	-$3.92	N/A	N/A	N/A	-1,387.98%	-1,010.74%	-33.27%	N/A
STOK Stoke Therapeutics	-$88.98M	$0.79	20.20	N/A	N/A	26.25%	18.32%	15.48%	N/A
TIL Instil Bio	-$74.14M	-$11.97	N/A	N/A	N/A	N/A	-51.67%	-32.77%	N/A

Latest TIL, QURE, DNA, and STOK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	TIL Instil Bio	-$1.72	-$3.24	-$1.52	-$3.24	N/A	N/A
8/12/2025	Q2 2025	STOK Stoke Therapeutics	-$0.57	-$0.40	+$0.17	-$0.40	$31.51 million	$13.82 million
8/7/2025	Q2 2025	DNA Ginkgo Bioworks	-$1.44	-$1.10	+$0.34	-$1.10	$41.60 million	$49.60 million
7/29/2025	Q2 2025	QURE uniQure	-$0.89	-$0.69	+$0.20	-$0.69	$5.00 million	$5.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNA Ginkgo Bioworks	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNA Ginkgo Bioworks	N/A	5.41	4.88
QURE uniQure	1.53	9.98	9.98
STOK Stoke Therapeutics	N/A	6.98	8.41
TIL Instil Bio	0.58	30.33	30.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNA Ginkgo Bioworks	78.63%
QURE uniQure	78.83%
STOK Stoke Therapeutics	N/A
TIL Instil Bio	60.56%

Insider Ownership

Company	Insider Ownership
DNA Ginkgo Bioworks	9.72%
QURE uniQure	4.79%
STOK Stoke Therapeutics	9.50%
TIL Instil Bio	47.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNA Ginkgo Bioworks	640	58.53 million	52.84 million	Optionable
QURE uniQure	500	54.87 million	52.24 million	Optionable
STOK Stoke Therapeutics	100	54.80 million	49.41 million	Optionable
TIL Instil Bio	410	6.56 million	3.46 million	No Data

TIL, QURE, DNA, and STOK Headlines

Recent News About These Companies

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13 at 11:10 AM | finanznachrichten.de

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13 at 6:00 AM | globenewswire.com

Instil Bio Reports Promising Phase 2 Study Results

August 11, 2025 | theglobeandmail.com

Instil Bio stock rises after positive data for cancer therapy in China

July 31, 2025 | za.investing.com

Instil's licensed PD-L1xVEGF bispecific shows promise in China, instilling hope for upcoming US test

July 31, 2025 | fiercebiotech.comF

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China

July 31, 2025 | globenewswire.com

US FDA clears Instil Bio’s IND application for AXN-2510, a PD-L1xVEGF bispecific antibody, for a phase 1 trial in relapsed/refractory solid tumours

July 4, 2025 | pharmabiz.comP

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed ...

July 3, 2025 | manilatimes.netM

Instil Bio Announces FDA Clearance for IND of AXN-2510, Phase 1 Trial Expected by End of 2025 - Nasdaq

July 3, 2025 | nasdaq.com

Instil Bio stock jumps after FDA clearance of IND application

July 2, 2025 | in.investing.com

Instil Bio Shares Climb After FDA Clears Tumor Treatment Application

July 2, 2025 | marketwatch.com

Instil Bio Shares Surge on FDA Clearance for Investigational Cancer Therapy

July 2, 2025 | msn.com

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

July 2, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/07/02/3109003/0/en/instil-bio-announces-u-s-f-d-a-clearance-of-investigational-new-drug-ind-application-for-axn-2510-a-pd-l1xvegf-bispecific-antibody-for-a-phase-1-trial-in-relapsed-refractory-solid-.html$

Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know

June 20, 2025 | zacks.com

Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet

June 16, 2025 | zacks.com

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

June 11, 2025 | globenewswire.com

Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice

June 4, 2025 | zacks.com

Instil Bio appoints new Chief Medical Officer

June 4, 2025 | uk.investing.com

Instil Bio appoints Jamie Freedman as Chief Medical Officer

June 2, 2025 | msn.com

Instil Bio, Inc. Appoints Jamie Freedman, M.D., Ph.D., as Chief Medical Officer to Propel Cancer Therapy Development

June 2, 2025 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TIL, QURE, DNA, and STOK Company Descriptions

Ginkgo Bioworks NYSE:DNA

$12.91 -0.35 (-2.65%)

Closing price 08/14/2025 03:59 PM Eastern

Extended Trading

$13.12 +0.21 (+1.60%)

As of 04:26 AM Eastern

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

uniQure NASDAQ:QURE

$15.78 +1.18 (+8.08%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$15.74 -0.04 (-0.29%)

As of 04:06 AM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Stoke Therapeutics NASDAQ:STOK

$17.17 +0.26 (+1.54%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$17.59 +0.42 (+2.45%)

As of 04:02 AM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Instil Bio NASDAQ:TIL

$28.25 +1.28 (+4.75%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$28.76 +0.51 (+1.81%)

As of 04:27 AM Eastern

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time